CN Patent

CN106397592A — 针对程序性死亡配体(pd-l1)的单域抗体及其衍生蛋白

Assigned to Suzhou Alphamab Co Ltd · Expires 2017-02-15 · 9y expired

What this patent protects

本发明涉及医药生物领域，公开了针对程序性死亡配体(PD-L1)的单域抗体及其衍生蛋白。具体而言，本发明公开了一种程序性死亡配体1(PD-L1)结合分子及其用途，特别是在治疗和/或预防、或诊断PD-L1相关疾病例如肿瘤中的用途。

USPTO Abstract

本发明涉及医药生物领域，公开了针对程序性死亡配体(PD-L1)的单域抗体及其衍生蛋白。具体而言，本发明公开了一种程序性死亡配体1(PD-L1)结合分子及其用途，特别是在治疗和/或预防、或诊断PD-L1相关疾病例如肿瘤中的用途。

Drugs covered by this patent

trilaciclib-dihydrochloride (TRILACICLIB DIHYDROCHLORIDE)

Patent Metadata

Patent number: CN106397592A
Jurisdiction: CN
Classification: —
Expires: 2017-02-15
Drug substance claim: No
Drug product claim: No
Assignee: Suzhou Alphamab Co Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.